VANCOUVER, British Columbia, Oct. 13, 2022 (GLOBE NEWSWIRE) -- SOLVE FSHD, a venture-philanthropic organization catalyzing the pace of innovation to accelerate a cure for facioscapulohumeral muscular ...

SOUTH SAN FRANCISCO, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today ...

Mirecule, Inc., a leader in Antibody RNA Conjugate (ARC) therapeutics targeting rare neuromuscular diseases, today announced an expansion of its strategic collaboration with Sanofi. This collaboration ...

Shares of small molecule developer Fulcrum Therapeutics (FULC) have lost more than 80% of their value since the IPO was priced at $19 in August 2021. Year to date performance is negative 50% after FTX ...

Facioscapulohumeral muscular dystrophy (FSHD) is a rare muscular disorder that results from a genetic mutation that leads to a shorter chromosome 4. This is a degenerative disease in which muscles of ...

After years of advocating for a cure for the rare disease that has limited his mobility, Mark Christman has made his way to Capitol Hill. Christman, a retired attorney and board member of Trib Total ...

The third annual National FSHD Walk & Roll virtual event will take place on Sept. 12. With a goal of finding a cure to facioscapulohumeral muscular dystrophy (FSHD) by 2025, the FSHD Society’s third ...

SAN DIEGO--(BUSINESS WIRE)--n-Lorem, a nonprofit foundation, today announced that Solve FSHD has provided one million dollars in support of n-Lorem’s efforts to fully understand the complex molecular ...

Armed with $68 million in Series B funding, Epicrispr Biotechnologies (Epic) is initiating human trials of its lead candidate EPI-321, an epigenetic therapy for the neuromuscular disorder, ...

When the global pandemic lockdown began, someone from my FSHD (fascio-scapular muscular dystrophy) Facebook group wrote: “Now at least everyone else knows what it feels like to be physically confined.